Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures often hide crucial trial milestones behind pages of pharmacology and risk factors. Allarity Therapeutics鈥� SEC filings are no different; they weave together DRP庐 companion-diagnostic data, stenoparib study designs, and cash-runway projections that can be hard to parse in real time.
Stock Titan eliminates that bottleneck. Our AI-powered summaries translate every 10-K and 10-Q into plain language, spotlighting R&D spend, enrollment updates, and financing terms. Need the latest Allarity Therapeutics quarterly earnings report 10-Q filing? It lands here the moment EDGAR posts, accompanied by sentence-level explanations. Prefer concise alerts? We surface Allarity Therapeutics 8-K material events explained and flag protocol amendments or data-readouts within minutes. For governance details, see the Allarity Therapeutics proxy statement executive compensation section鈥攐ur platform links compensation shifts to pipeline progress so you can understand incentives at a glance.
Monitoring management confidence is just as easy. Receive real-time notifications for Allarity Therapeutics Form 4 insider transactions real-time and dig deeper into each Allarity Therapeutics insider trading Form 4 transactions record. Historical tables let you trace buying patterns, while AI notes summarize context around each trade. Whether you鈥檙e comparing quarter-over-quarter burn rates, seeking an Allarity Therapeutics annual report 10-K simplified, or simply understanding Allarity Therapeutics SEC documents with AI, our coverage keeps every filing type鈥�10-K, 10-Q, 8-K, S-3, and more鈥攁t your fingertips. Save hours of manual reading and focus on what matters: assessing the science, the cash, and the insider signals that shape Allarity鈥檚 future.
Allarity Therapeutics, Inc. reported interim results showing constrained operations but sufficient near-term liquidity. The company recorded a net loss of $5.1 million for the six months ended June 30, 2025 and negative operating cash flow of $8.2 million over the same period. Management states that $17.8 million of cash, cash equivalents and restricted cash as of June 30, 2025 is estimated to be sufficient to fund operations for at least the next 12 months under the current plan. The company completed corporate actions including Reverse Stock Splits (retroactively applied) and repurchased 2,455,702 shares for $2,565,511, leaving $2,434,489 available under its repurchase program. A legal/contract liability to Novartis resulted in current liabilities recorded as $3.6 million accounts payable, $1.4 million convertible promissory notes and accrued interest, and $0.4 million accrued liabilities. The company settled a prior SEC investigation by paying a $2.5 million civil penalty which was paid in cash on April 2, 2025.
On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.
No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.
Allarity Therapeutics has formally requested the withdrawal of its Form S-3 registration statement (File No. 333-281864) filed on August 30, 2024. The company has decided not to proceed with the planned public offering at this time.
Key points from the withdrawal request:
- The registration statement was never declared effective by the SEC
- No securities were issued or sold under this registration
- The company acknowledges no refund will be made for filing fees
- Allarity requests that paid fees be credited to offset future registration statement costs under Rule 457(p)
The withdrawal request, submitted by CEO Thomas H. Jensen on June 24, 2025, is made pursuant to Rule 477 under the Securities Act of 1933. This action indicates a significant shift in the company's capital raising strategy and could impact its near-term financing plans.
FAQ
What is the current stock price of Allarity (ALLR)?
What is the market cap of Allarity (ALLR)?
